Quick Answer
BICYCLE THERAPEUTICS PLC reported Operating Income Loss of -$247.07 million for the year ending 2025.
- BICYCLE THERAPEUTICS PLC showed a decrease of -17.7% in Operating Income Loss from 2024 to 2025.
- This data is from BICYCLE THERAPEUTICS PLC's annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: -$4.96 million | Q3 2018: -$6.36 million | Q1 2019: -$3.29 million | Q2 2019: -$7.99 million | Q3 2019: -$10.25 million | Q1 2020: -$11.64 million | Q2 2020: -$12.58 million | Q3 2020: -$10.68 million | Q1 2021: -$16.02 million | Q2 2021: -$17.28 million | Q3 2021: -$14.29 million | Q1 2022: -$27.38 million | Q2 2022: -$27.30 million | Q3 2022: -$29.76 million | Q1 2023: -$41.80 million | Q2 2023: -$43.11 million | Q3 2023: -$50.80 million | Q1 2024: -$31.72 million | Q2 2024: -$46.65 million | Q3 2024: -$63.85 million | Q1 2025: -$70.20 million | Q2 2025: -$86.60 million | Q3 2025: -$65.55 million.
- Over the full 9 years of available data (2017 to 2025), BICYCLE THERAPEUTICS PLC's Operating Income Loss has declined by 1,423.9%.
- Historical annual values: Fiscal year 2025: -$247.07 million | Fiscal year 2024: -$209.87 million | Fiscal year 2023: -$189.95 million | Fiscal year 2022: -$116.65 million | Fiscal year 2021: -$65.62 million | Fiscal year 2020: -$51.96 million | Fiscal year 2019: -$26.30 million | Fiscal year 2018: -$21.75 million | Fiscal year 2017: -$16.21 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: